Verseon Gains US Patent Protection for Compounds that Could Eliminate Bleeding Risks of Current Anticoagulants

News provided by

Jan 24, 2024, 08:42 ET

"They could greatly improve the standard of care for several hundred million underserved patients around the world," says Verseon's CSO David Kita

FREMONT, Calif., Jan. 24, 2024 /PRNewswire/ -- Verseon is pleased to announce that the USPTO has issued a new patent, "Thrombin Inhibitors, Formulations, and Uses Thereof," that further extends intellectual property protection for Verseon's novel class of thrombin inhibitors. These anticoagulant compounds promise to open new and safer treatment options for many of the world's 400+ million cardiovascular disease patients.

Patients with cardiovascular disease are often at risk of strokes and heart attacks and would likely benefit from lifelong use of an anticoagulant, either alone or in combination with an antiplatelet drug. Unfortunately, the bleeding risk posed by all anticoagulants currently on the market is high when these drugs are used by themselves – and typically unacceptable when used together with blood-thinning antiplatelet drugs.

Unlike current anticoagulants, Verseon's Precision Oral Anticoagulants (PROACs) covered by this patent exhibit a unique mechanism of action that does not increase the risk of bleeding yet prevents the formation of the dangerous blood clots behind heart attacks and strokes. Because these compounds are also highly selective against other serine proteases, they are expected to cause fewer side effects. Further, their innovative mechanism of action does not inhibit thrombin-mediated platelet activation, making them well suited for long-term combination therapy with antiplatelet drugs.

"We are pleased by the USPTO's decision to grant additional patent protection for our PROACs," said Verseon's CSO David Kita. "They could greatly improve the standard of care for several hundred million underserved patients around the world."

Verseon's scientists consistently find new drug candidates that have never before been designed or synthesized. The company's breakthroughs in physics- and AI-driven molecule engineering allows them to chart previously unexplored parts of small molecule chemical space – and create new drug candidates with unique treatment profiles that promise to change the standard of care for many therapeutic indications.

About Verseon

Verseon International Corporation (www.verseon.com) is transforming the delay, prevention, and treatment of disease. Using its Deep Quantum Modeling + AI platform, Verseon is rolling out a steady stream of life-changing medicines. Each of the company's drug programs features multiple novel candidates with unique therapeutic properties. None of these candidates can be found by other current methods. Verseon's fast-growing pipeline addresses major human diseases in the areas of cardiometabolic disorders and cancers.

Media Contact

Walter Jones
(510) 225-9000
[email protected]

SOURCE Verseon International Corporation